Business Description
Macrogenics Inc
NAICS : 325412
SIC : 2834
ISIN : US5560991094
Description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.42 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -2.65 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -4.69 | |||||
| Beneish M-Score | -5.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.9 | |||||
| 3-Year EPS without NRI Growth Rate | -1.6 | |||||
| 3-Year FCF Growth Rate | 16.9 | |||||
| 3-Year Book Growth Rate | -22.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 18.45 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.63 | |||||
| 9-Day RSI | 21.79 | |||||
| 14-Day RSI | 23.83 | |||||
| 6-1 Month Momentum % | 113.13 | |||||
| 12-1 Month Momentum % | 172 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.63 | |||||
| Quick Ratio | 3.61 | |||||
| Cash Ratio | 3.3 | |||||
| Days Inventory | 68.42 | |||||
| Days Sales Outstanding | 149.26 | |||||
| Days Payable | 299.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.3 | |||||
| Shareholder Yield % | -1.88 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 83.7 | |||||
| Operating Margin % | -439.15 | |||||
| Net Margin % | -55.59 | |||||
| FCF Margin % | -272.47 | |||||
| ROE % | -15.84 | |||||
| ROA % | -7.57 | |||||
| ROIC % | -261.49 | |||||
| ROC (Joel Greenblatt) % | -43.3 | |||||
| ROCE % | -8.32 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 16.02 | |||||
| PS Ratio | 6.89 | |||||
| PB Ratio | 2.73 | |||||
| Price-to-Tangible-Book | 2.72 | |||||
| EV-to-EBIT | -6.55 | |||||
| EV-to-EBITDA | -10.89 | |||||
| EV-to-Revenue | 3.34 | |||||
| EV-to-Forward-Revenue | 2.59 | |||||
| EV-to-FCF | -1.23 | |||||
| Price-to-Median-PS-Value | 0.82 | |||||
| Price-to-Net-Current-Asset-Value | 4.76 | |||||
| Price-to-Net-Cash | 6.9 | |||||
| Earnings Yield (Greenblatt) % | -15.27 | |||||
| FCF Yield % | -39.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Macrogenics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 38.646 | ||
| EPS (TTM) (€) | -0.35 | ||
| Beta | 1.74 | ||
| Volatility % | 76.16 | ||
| 14-Day RSI | 23.83 | ||
| 14-Day ATR (€) | 0.778234 | ||
| 20-Day SMA (€) | 9.1073 | ||
| 12-1 Month Momentum % | 172 | ||
| 52-Week Range (€) | 3.102 - 19.8 | ||
| Shares Outstanding (Mil) | 62.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Macrogenics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Macrogenics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Macrogenics Inc Frequently Asked Questions
What is Macrogenics Inc(FRA:M55)'s stock price today?
The current price of FRA:M55 is €4.14. The 52 week high of FRA:M55 is €19.80 and 52 week low is €3.10.
When is next earnings date of Macrogenics Inc(FRA:M55)?
The next earnings date of Macrogenics Inc(FRA:M55) is 2024-08-09 Est..
Does Macrogenics Inc(FRA:M55) pay dividends? If so, how much?
Macrogenics Inc(FRA:M55) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers